BRAF and lymphangioma: In a case series of 14 melanoma patients with LM reported by Arasaratnam et al., the median OS of patients receiving ipilimumab, anti-PD1 and BRAF inhibitors were 3 months, 7.1 months, and 7.2 months respectively [11].